Loading clinical trials...
Loading clinical trials...
A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Conditions
Interventions
berubicin hydrochloride (RTA 744)
Locations
7
United States
Palm Beach Cancer Institute
West Palm Beach, Florida, United States
Presbyterian Health Care
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Moses Cone Regional Cancer Center
Greensboro, North Carolina, United States
Forsyth Regional Cancer Center
Winston-Salem, North Carolina, United States
Texas Oncology, PA
Dallas, Texas, United States
Start Date
October 31, 2007
Primary Completion Date
December 1, 2008
Completion Date
January 1, 2009
Last Updated
May 29, 2025
NCT07462507
NCT06253871
NCT05987644
NCT05692635
NCT07130786
NCT07464470
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions